Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809367 | 0.90 | CYP1A2 (0.53) | KDM4ECYP1A2ALDH1A1HPGDHTT | |
| SCHEMBL14306188 | 0.87 | CYP1A2 (0.46) | KDM4ECYP1A2ALDH1A1HPGDHTT | |
| SCHEMBL8647610 | 0.81 | CYP1A2 (0.41) | KDM4ECYP1A2ALDH1A1HPGDHTT | |
| SCHEMBL2423817 | 0.81 | KDM4E (0.47) | KDM4ECYP1A2ALDH1A1HPGDHTT | |
| SCHEMBL3706189 | 0.81 | KDM4E (0.42) | KDM4ECYP1A2ALDH1A1HPGDHTT | |
| SCHEMBL311179 | 0.80 | KDM4E (0.35) | KDM4ESMN1; SMN2LMNATSHR | |
| SCHEMBL10067668 | 0.80 | LMNA (0.46) | KDM4ECYP1A2ALDH1A1HPGDHTT | |
| SCHEMBL20745198 | 0.80 | CYP1A2 (0.50) | KDM4ECYP1A2ALDH1A1HPGDHTT | |
| SCHEMBL5563489 | 0.80 | RAB9A (0.50) | CYP1A2ALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL162807 | 0.79 | ALDH1A1 (0.46) | KDM4ECYP1A2ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404246-B1 | 2-aminomethylimidazole mimics of NS4A and their effect thereof on hepatitis C virus NS3 protease | KING ABDULAZIZ UNIVERSITY (SA) | 2025-09-02 | — | — | US | disclosed |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | KING ABDULAZIZ UNIVERSITY (SA) | 2021-03-30 | — | — | US | disclosed |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | KING ABDULAZIZ UNIVERSITY (SA) | 2021-03-30 | — | — | US | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-26 | — | — | US | disclosed |
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-26 | — | — | US | disclosed |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-03 | — | — | US | disclosed |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-03 | — | — | US | disclosed |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | KING ABDULAZIZ UNIVERSITY (SA) | 2020-10-15 | — | — | US | disclosed |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | KING ABDULAZIZ UNIVERSITY (SA) | 2020-10-15 | — | — | US | disclosed |
| EP-2273882-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | Poniard Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-6057454-A | USEFUL FOR TREATING OR PREVENTING ALL ISCHAEMIAS (SUCH AS FOCAL OR GLOBAL ISCHAEMIA) RESULTING FROM CEREBROVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2000-05-02 | — | — | US | disclosed |
| EP-0772615-B1 | IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE POULENC RORER SA (FR) | 1999-09-22 | — | — | EP | disclosed |
| US-5902803-A | 5H,10H-imidazo 1,2-a!indeno 1,2-e!pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives | RHONE-POULENC RORER S.A. (FR) | 1999-05-11 | — | — | US | disclosed |
| US-5726175-A | MULTISTAGE PROCESS WITH CYCLIZATION AND AMINATION | RHONE-POULENC RORER S.A. (FR) | 1998-03-10 | — | — | US | disclosed |
| WO-1997025326-A1 | 2-SUBSTITUTED 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1997-07-17 | — | — | WO | disclosed |
| EP-0772615-A1 | IMIDAZO 1,2-a]INDENO 1,2-e]PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996002544-A1 | IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | MAVS, CUL1, CUL3 | KDM4E 2114/4885CYP1A2 1431/4885ALDH1A1 3525/4885 |
| US-12404246-B1 | 2-aminomethylimidazole mimics of NS4A and their effect thereof on hepatitis C virus NS3 protease | DPP4, GTF3C4, CTRL | KDM4E 465/4885CYP1A2 156/4885ALDH1A1 1725/4885 |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, ZC3HAV1 | KDM4E 1213/4885CYP1A2 117/4885ALDH1A1 1548/4885 |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | MAVS, CUL1, CUL3 | KDM4E 2114/4885CYP1A2 1431/4885ALDH1A1 3525/4885 |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | HAVCR2, MAVS, ZC3HAV1 | KDM4E 1213/4885CYP1A2 117/4885ALDH1A1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.